

1 **The QuantuMDx Q-POC™ SARS-CoV-2 RT-PCR assay for rapid detection of COVID-19 at**
2 **point-of-care: preliminary evaluation of a novel technology**

3
4 **Jessica Caffry^{1*}, Matthew Selby^{1*}, Katie Barr¹, George Morgan¹, David McGurk¹, Philip**
5 **Scully¹, Catherine Park¹, Anna-Maria Caridis¹, Emily Southworth¹, Jack Morrison¹, David J**
6 **Clark², Nickolas Eckersely², Elisabetta Gropelli², Daniela E. Kirwan², Irene Monahan²,**
7 **Yolanda Augustin², Colin Toombs¹, Tim Planche^{2,3}, Henry M Staines^{2**}, Sanjeev Krish-**
8 **na^{2,3,4,5**}**

9
10 ¹ QuantuMDx, Lugano Building, 57 Melbourne St, Newcastle upon Tyne, UK

11 ² Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for In-
12 fection & Immunity, St George's University of London, London, UK

13 ³ St George's University Hospitals NHS Foundation Trust, UK

14 ⁴ Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany

15 ⁵ Centre de Recherches Médicales de Lambaréné, Gabon

16
17 * Equal contribution: Jessica Caffry & Matthew Selby

18 ** Corresponding authors: Sanjeev Krishna s.krishna@sgul.ac.uk

19 Henry Staines hstaines@sgul.ac.uk

20

21

22

23 **Abstract**

24 **Background:** Accurate, affordable, and rapid point-of-care (PoC) diagnostics are critical to the
25 global control and management of the COVID-19 pandemic. The current standard for accurate
26 diagnosis of SARS-CoV-2 is laboratory-based reverse transcription polymerase chain reaction
27 (RT-PCR). Here, we report a preliminary prospective performance evaluation of the QuantuMDx
28 Q-POC™ SARS CoV-2 RT-PCR assay.

29 **Methods:** Between November 2020 and March 2021, we obtained 49 longitudinal nose and
30 throat swabs from 29 individuals hospitalised with RT-PCR confirmed COVID-19 at St George's
31 NHS Foundation Trust, London (UK). In addition, we obtained 101 mid nasal swabs from
32 healthy volunteers in June 2021. We then used these samples to evaluate the Q-POC™ SARS-
33 CoV-2 RT-PCR assay. The primary analysis was to compare the sensitivity and specificity of the
34 Q-POC™ test against a reference laboratory-based RT-PCR assay.

35 **Results:** The overall sensitivity of the Q-POC™ test compared with the reference test was
36 96.88% (83.78%- 99.92% CI) for a cycle threshold (Ct) cut-off value for the reference test of 35
37 and 80.00% (64.35% to 90.95% CI) without altering the reference test's Ct cut-off value of 40.

38 **Conclusions:** The Q-POC™ test is a sensitive, specific and rapid point-of-care test for SARS-
39 CoV-2 at a reference Ct cut-off value of 35. The Q-POC™ test provides an accurate and afford-
40 able option for RT-PCR at point-of-care without the need for sample pre-processing and labora-
41 tory handling. The Q-POC™ test would enable rapid diagnosis and clinical triage in acute care
42 and other settings.

43

44 **Key words**

45 Diagnostics, RT-PCR, Point-of-care, COVID-19, SARS-CoV-2

46

47 **Introduction**

48 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive
49 sense, single-stranded RNA viruses of the genus betacoronavirus that caused the corona virus
50 disease 2019 (COVID-19) pandemic with devastating public health impact. As of 24th June
51 2021, there have been more than 180 million individuals infected and almost 4 million deaths
52 globally (1). The first diagnostic assays for this disease were developed shortly after the initial
53 publication of the viral genome in January 2020 (2). These were nucleic acid amplification tests
54 (NAATs) based on reverse transcriptase polymerase chain reaction (RT-PCR), where target vi-
55 ral RNA sequences are converted to DNA and exponentially amplified to allow detection with
56 fluorescent probes. The lower the concentration of target RNA sequence in a clinical sample,
57 the higher the cycle threshold (Ct) value at which fluorescence is detectable.

58
59 Most convenient assays use upper respiratory (e.g. nasopharyngeal or oropharyngeal or nose
60 and throat) swab samples to detect SARS-CoV-2 RNA and are highly sensitive (e.g. (3)). Viral
61 load is highest in the upper respiratory tract in the first week of illness (4). However, standard
62 laboratory-based RT-PCR assays are relatively complex and time consuming, requiring highly
63 trained personnel and expensive equipment based in a centralised laboratory. They take sev-
64 eral hours to perform in batches, and, when time is added for sample transport, results often
65 take 24 hours or more to be reported. This can result in delayed diagnosis, which can compli-
66 cate clinical triage.

67
68 Point-of-care (PoC) diagnostics were identified as one of eight key research priorities to tackle
69 the pandemic (5). Rapid, PoC or near-patient testing for active infections confers several bene-
70 fits over laboratory-based testing including faster triage, which in turn aids infection control and
71 clinical management. Rapid PoC tests can also enable effective community testing and alleviate
72 pressure on overburdened centralised labs. While lateral flow-based rapid antigen tests (RDTs)

73 are now in widespread use, they are less sensitive than NAATs (6). Thus, development of rapid
74 PoC NAAT-based tests are a priority, especially for use when immediate actions are needed for
75 positive cases such as in accident and emergency departments, pre-surgical or chemotherapy
76 day unit admissions, care homes, airports, prisons and low resource healthcare settings. Sev-
77 eral versions of PoC NAATs have been developed (7-10), but all have one or more limitations
78 including long sample-to-result times, complexity (steps required) and cost.

79
80 To address the urgent need for a rapid and sensitive COVID-19 diagnostic, QuantuMDx have
81 repurposed their RT-PCR PoC diagnostics platform, the Q-POC™, to run a SARS-CoV-2 assay.
82 Here, we present a detailed description of this technology and a preliminary prospective per-
83 formance evaluation of Q-POC™ compared with validated laboratory-based RT-PCR assays.

84 **Methods**

85 *Ethical statement*

86 Ethical approval for clinical sample use at SGUL was provided by the Institutional Review Board
87 as part of the “Development and Assessment of Rapid Testing for SARS-CoV-2 outbreak”
88 (DARTS) study, sponsored by St George’s Hospital NHS Foundation Trust (Integrated Re-
89 search Application System project ID: 282104; South Central - Oxford C Research Ethics
90 Committee reference: 20/SC/0171; registered at clinicaltrials.gov NCT04351646). All partici-
91 pants for this study were recruited following informed consent.

92

93 *Swab samples*

94 Patients with COVID-19 hospitalised at St George’s Hospital were recruited into the prospective
95 study between 19th November 2020 and 3rd March 2021 (inclusive). Prior to recruitment, they
96 were confirmed as positive for SARS-CoV-2 using RT-PCR from nose and throat swabs (in
97 Sigma Virocult®, Corsham, UK) and Roche RNA extraction kits (Magpure, West Sussex, UK)
98 followed by Altona Diagnostics RealStar® SARS-CoV-2 RT-PCR (S and E target genes, Ham-
99 burg, Germany) or Roche cobas® SARS-CoV-2 Test (E and ORF target genes). All patients
100 consented to nose and throat swabs being taken. Following recruitment to DARTS, longitudinal
101 nose and throat swab samples were collected, using a Copan swab (Cat number: 503CS01).
102 Samples were stored within 2 hours, without viral transport medium, at -80 C until use. In addi-
103 tion, anonymised mid-nasal swab samples were collected between 15th to the 18th June 2021
104 (inclusive) from healthy staff volunteers at QuantuMDx following informed consent and tested
105 immediately.

106

107 *Q-POC™ testing*

108 The Q-POC™ device is a PoC diagnostics platform, which runs a rapid molecular test in a sin-
109 gle use microfluidic cassette (Q-CAS) by incorporating sample processing, DNA amplification

110 (with RT step, if required), and downstream semi-quantitative detection of pathogens in small
111 volumes of sample.

112
113 For detection of SARS-CoV-2 by RT-PCR at PoC a flexible mini tip Copan FLOQSwab (de-
114 signed for nasopharyngeal sampling) was used to take a nose and throat or a mid nasal swab.
115 The tip (fresh or defrosted) was then broken off into a sample tube containing 3 ml of MSwab™
116 sample collection, transport and preservation medium (Copan Diagnostics, Italy). Following
117 sample tube inversion (x5), a 400 µl aliquot is pipetted into a test cassette, Q-CAS (Figure 1)
118 and sealed in with a cap.

119
120 The loaded cassette is then scanned and loaded into the Q-POC™ device. Within the Q-CAS,
121 reconstitution of lyophilised RT-PCR reagents, held within sealed ‘Reagent Fuses’ for increased
122 shelf-life, occurs using 50 µl of the swab eluate containing released RNA. Following an RT step,
123 rapid PCR is achieved by shuttling fluid between heating zones (shuttle flow PCR, sfPCR – Fig.
124 1B). This allows target amplification in approximately 32 minutes. SARS-CoV-2 gene targets
125 (Orf1ab, N and S) and an RNaseP (control) are detected by fluorescence readings taken after
126 each cycle (qPCR reader), for semi-quantitative analysis. The use of individual heating zones
127 combined with shuttling of the fluid, unlike the temperature ramping used by conventional PCR,
128 is far more energy efficient allowing for multiple assay runs even when the Q-POC™ is battery
129 operated. The Q-POC™ is front-loading and intuitive, with a simple touch screen interface de-
130 signed for PoC testing in resource limited settings. It contains all the necessary mechanics,
131 electronics and optics to drive the cassette-based assays, in addition to reading, interpreting
132 and presenting test results. It is portable and operable either on mains power or by an ex-
133 changeable battery, which can last up to 4 h. Data are recorded and initially stored on the Q-
134 POC™ within a secured database, with a storage capacity of >1000 patient results. In addition,
135 the Q-POC™ will connect to a specified receipt-style printer. The Q-POC™ operating system

136 runs on an ARM-based processing board integrating connectivity options: GPS, Bluetooth, Wi-Fi
137 and GPRS (2G/3G) connectivity. Operation data are also retained within the Q-POC™ to allow
138 for tracking and trending of instrument performance.

139

140 *Laboratory based reference testing*

141 An aliquot (140 µl) of each swab sample in 3 ml of MSwab was used with a QIAamp Viral RNA
142 Mini Kit (Qiagen, Germany) for RNA extraction, as per the manufacturer's instructions. The CE-
143 marked SARS-CoV-2 RT-PCR Detection Assay (QuantuMDx, UK) was used as the reference
144 test. It is based on TaqMan chemistry and utilises FAM for the detection of the three SARS-
145 CoV-2 loci, Orf1ab, N gene and the S gene and HEX for the detection of the RNase P gene (a
146 specimen and process control).

147

148 *Statistical analysis*

149 Operators were not blinded to the status of patients/volunteers from which the samples were
150 taken prior to Q-POC™ testing but did not have access to the results of the subsequent refer-
151 ence testing; however, the Q-POC™ requires no subjective interpretation of a result.

152 Data were analysed with GraphPad Prism (version 6.07 for Windows). Diagnostic sensitivity,
153 specificity, positive predictive value and negative predictive value were determined, using the
154 laboratory-based RT-PCR as a reference standard (Supplementary data). Samples that were
155 invalid on the PoC platform were not included in the primary sensitivity analysis. The manuscript
156 was prepared in accordance with the EQUATOR Network's STARD guidelines (Supplementary
157 checklist).

158

159

160 **Results**

161 Swab samples (n = 150) were collected and tested, using the Q-POC™ (Fig. 2). Two cohorts
162 were recruited. In the first, hospitalised patients at St George's Hospital with an RT-PCR con-
163 firmed COVID-19 diagnosis were clinically assessed between the 19th November 2020 and 3rd
164 March 2021 as part of DARTS. The recruits provided longitudinal samples predicted to have a
165 wide range of viral loads thereby provide a challenging sample set for initial evaluation of the Q-
166 POC™. Patients (n = 29) who provided a nose and throat sample, using a mini tip Copan swab,
167 were eligible for inclusion in the Q-POC™ evaluation. One patient's sample produced an invalid
168 test result and was not retested. This patient provided only one sample so, while the invalid re-
169 sult is included in the analysis (Fig. 2), the patient is not (Table 1). Therefore, complete clinical
170 data paired with laboratory tests were available for 28 patients and 47 samples. Participants
171 formed a convenience series. No adverse events from performing the Q-POC™ or the refer-
172 ence test were recorded.

173
174 The median age of COVID-19 positive study participants included in the analysis was 64.5 (IQR
175 51-75), 19 (68%) were male, 15 (54%) were symptomatic and the majority (23; 82%) had mild
176 disease at enrolment (Table 1). In the second cohort, 101 mid nasal Copan swab samples were
177 collected from healthy volunteer staff to provide a SARS-CoV-2 negative dataset. Of these, 1
178 sample returned an invalid test result and was not retested. Therefore, test data for further
179 analysis were available for 100 samples from this cohort (Fig. 2). Of the total 155 sample runs
180 on the Q-POC™ there were 8 invalid runs, 5 of which were retested to produce valid results,
181 and 3 of which were not retested as the sample was destroyed (Fig. 2). This gives an invalid
182 rate over the study period of 5.2%.

183
184 Figure 3 presents the Ct values from the reference test used with longitudinal nose and throat
185 swab samples from COVID-19 positive participants. As predicted, this sample set provided a

186 wide range of viral loads (using Ct values as a basic proxy), including multiple samples between
187 Ct values of 30 and 40. Included in the graph are the available Ct data from the hospital test un-
188 dertaken prior to enrolment (for 22 of the 28 participants). The day the swab was taken for this
189 test was used as day 0. Two different validated assays (see Methods) were used at St George's
190 Hospital over the study period. Irrespective of the test used, there is an increase in Ct values
191 with time after the first test. No participants with a hospital test Ct value below 26 produced a
192 negative result within the short (12 day) study period, while several participants with a starting
193 hospital Ct value above 26 were negative at subsequent time points.

194

195 Prior to the reference RT-PCR testing undertaken to derive the data presented in Figure 3,
196 samples were run on the Q-POC™ SARS-CoV-2 RT-PCR assay. While the assay is designed
197 to generate a SARS-CoV-2 positive or negative result, Ct values can also be derived. Figure 4
198 compares Ct values for the reference versus the Q-POC™ test. Data are from samples that
199 were called positive by both tests (n = 32) and thus have paired Ct data. The two datasets
200 passed normality tests (P = 0.86 and P = 0.69 for the reference and Q-POC™ tests, respec-
201 tively; D'Agostino & Peatson omnibus normality test). Interestingly, there is very good concor-
202 dance between the two paired datasets (as judged by eye, Fig.4A). Linear regression analysis
203 of Q-POC™ and reference datasets (Fig. 4B) show a strong correlation ($r^2 = 0.76$). A Bland-
204 Altman plot demonstrated very good agreement between the 2 tests, with a bias of -6.7 Ct units
205 meaning the Q-POC™ averages a 6.7 higher Ct value with mean (\pm SEM) Ct values of $25.8 \pm$
206 0.9 versus 32.5 ± 0.9 for the reference and Q-POC™ tests respectively. This measured bias is
207 consistent with the Ct cut-off value of 40 (above which a result is called negative) for the refer-
208 ence assay compared with the Ct cut-off value of 45 for the Q-POC™ assay.

209

210 With the inclusion of data from the 47 samples from COVID-19 patients and from single sam-
211 ples from 100 healthy volunteers the performance characteristics of the Q-POC™ test were de-

212 terminated (Table 2). The overall sensitivity (95% CI) of the Q-POC™ test was 80.0% (64.4-
213 91.0%) against the SARS-CoV-2 RT-PCR laboratory reference test with a specificity and 99.1%
214 (94.9-100%), with PPV and NPV of 97.0% and 93.0%, respectively. However, if the reference
215 test Ct cut-off was adjusted to <35, sensitivity increased significantly to 96.9% (83.8-99.9%),
216 while specificity dropped slightly to 98.3% (82.2-99.9%).

217
218 Of note, while not evaluated in this study, the instructions for use (IFU; Supplementary material)
219 for the Q-POC™ test states that the limit of detection is 1,000 genome equivalent copies per ml
220 with a standard deviation of 0.8 and average Ct of 41.89, which is in line with the results pre-
221 sented above. Furthermore, *in vitro* analysis for exclusivity or cross-reaction was undertaken
222 with no cross-reactivity observed under the tested conditions. All micro-organisms were used at
223 a concentration of 1×10^5 colony forming units (cfu) per reaction. Finally, as recommended by the
224 Medicines & Healthcare products Regulatory Agency (MRHA), UK, QuantuMDx continuously
225 monitor and assess the assay design *in silico* for newly emerging variants of SARS-CoV-2 with
226 regular reports which are published by MHRA.

227 **Discussion**

228 In a pandemic that causes a Public Health Emergency of International Concern, one of the ear-
229 liest interventions is accurate diagnosis of an infection. At the start of a pandemic, this will de-
230 pend largely on clinical evaluations (including imaging, biochemical and haematological as-
231 sessments) that guide immediate containment measures. NAATs can be developed with ur-
232 gency to diagnose a highly transmissible infectious disease accurately and assist in managing
233 patients and breaking transmission chains (as happened with COVID-19 (2)). Accurate diagnos-
234 tics are also critical to support the development of new therapeutic interventions, and to assess
235 public health measures to contain infections, including the development and implementation of
236 vaccination programmes.

237
238 There are several challenges for developers of diagnostics in the early stages of a pandemic.
239 Regulatory authorities will be as unfamiliar with a disease such as COVID-19 as are other ex-
240 perts and this may delay appropriate evaluation of tests under development. Urgent need cou-
241 pled with limited supplies and a motive to profit can encourage the proliferation of diagnostic
242 tests that are easy to produce in bulk (such as lateral flow assays) but that fail to meet minimum
243 requirements for accuracy (even if these requirements have been agreed, which itself can take
244 too long procedurally). One way to circumvent some of these limitations is to repurpose high
245 quality NAAT based testing platforms to deal with new infections such as caused by SARS-
246 CoV-2.

247
248 The COVID-19 pandemic highlighted an urgent need for PoC methods to detect SARS-CoV-2,
249 including its variants. To address this, QuantuMDx initially developed a laboratory based multi-
250 plex assay with simple to use lyophilised reagents that are stable when stored at room tempera-
251 ture, and quicker to run than many others (see (3)). However, these tests require automated
252 equipment and batch testing, and cannot give rapid results for individual assessment.

253

254 QuantuMDx therefore repurposed cassettes, the portable analytical platform and software to
255 provide an accurate, affordable and simple to use PoC test for SARS-CoV-2, as detailed in
256 Methods. Here it is demonstrated that using a reference test Ct cut-of 35 that the Q-POC™ test
257 for SARS-CoV-2 had a sensitivity of 96.88% (83.78%- 99.92% CI) and a specificity of 98.3%
258 (82.2-99.9%). These performance characteristics are comparable or better than other PoC
259 NAAT devices (7-10).

260

261 Advantages of the Q-POC™ include a rapid run-time (~32 minutes) compared with laboratory-
262 based diagnostic platforms and some PoC NAAT devices also (e.g. (7, 8)). The Q-POC™ swab
263 buffer is loaded directly into a fully sealed cartridge without the need for any extraction or sam-
264 ple processing steps. The sealed cartridge system also allows safe testing outside a laboratory,
265 including primary care and community settings. Consistent with improvements in manufacturing,
266 following preliminary evaluation (above) the cartridge failure rate ('invalid result' category) is ex-
267 pected to be < 2% and within specifications and industry standards. Centralised RT-PCR testing
268 has the advantage of higher throughput capability with Q-POC™ being able to process only one
269 cartridge at a time. This can be mitigated to an extent depending on the clinical setting and clini-
270 cal testing algorithm by using multiple processing units with random access for each.

271

272 Ct values as an estimate of viral load and/or infectiousness can be influenced by many variables
273 such as the site and methods for sample collection, the choice of diagnostic targets within the
274 viral genome and sample quality (11). In establishing cut-off values a key principle is that the
275 clinical risk of transmission must be minimised, so that chains of transmission are effectively in-
276 terrupted. Several reports have suggested a Ct cut-off for reference RT-PCR tests of <35 (12-
277 14). When Ct values are assessed in relation to the ability to culture virus results there are <3%

278 culture positive samples with Ct = 35 (15). This Ct cut-off value is the most clinically relevant,
279 because samples with higher cut-off Ct values are non-infectious and therefore could be termed
280 'biological false positives' despite being frequently (with up to 50% of positive results in assays
281 having higher Ct cut-off values) detected (16). At a reference test cut-off Ct ≥ 35 , the Q-POC™
282 test has excellent performance characteristics, that can be further examined in larger clinical
283 trials. Testing strategies can be optimised for individual use cases, such as for travellers, health-
284 care workers, prison services, triage of patients coming to emergency departments, wherever
285 there is no laboratory and for contacts at risk of infection by timing testing strategies appropri-
286 ately and by repeating testing at intervals when indicated.

287
288 Our study has several limitations. Although the sample size was small, it has been intended to
289 assess and optimise performance of this novel technology not to develop individual use cases.
290 Secondly, paired swab samples were not used for the reference and the Q-POC™ test rather
291 both tests were run from a single swab sample. While this might remove the variable associated
292 with multiple sampling from a participant subject at any given time point, the samples were
293 placed into 3 ml of MSwab buffer (required for the Q-POC™ test) rather than the normal 1 ml of
294 viral transport medium used in general for laboratory-based RT-PCR reference tests. This may
295 have the effect of decreasing the reference test sensitivity by a small margin. Thirdly, the sam-
296 ples collected from the COVID-19 patients were not accordance with the IFU for the Q-POC™
297 test, which uses MN swabs. Further comparative studies would be needed to determine if nose
298 and throat swabs can be used without loss of sensitivity, although it is worth noting that a small
299 study found no difference in diagnostic sensitivity when comparing nose and throat and naso-
300 pharyngeal swabs (17).

301

302 **Competing interests**

303 JC, MS, KB, GM, DM, PS, CP, A-MC, ES, JM and CT are employees of QuantuMDx. SK and
304 HMS are shareholders and SK is advisor to QuantuMDx. SK, HMS and EG are in receipt of
305 funds from QuantuMDx to develop diagnostic technologies and assays (that have supported
306 DJC). SK is also member of the Scientific Advisory Committee for the Foundation for Innovative
307 New Diagnostics (FIND), a not-for-profit organisation that produces global guidance on afford-
308 able diagnostics, views expressed here do not represent FIND. All other authors have no con-
309 flicts of interest to declare.

310

311 **Author contributions**

312 Conceptualization: JC, MS, PS, CT, TP, HMS, SK. Methodology: JC, MS, KB, GM, PS, DEK,
313 YA, CT, TP, HMS, SK. Investigation: KB, GM, DM, CP, A-MC, ES, JM, DJC, NE, EG, DEK, IM.
314 Formal Analysis: JC, MS, DM, KB, YA, TP, HMS, SK. Writing – Original Draft: JC, YA, HMS,
315 SK. Writing – Review & Editing: All.

316

317 **Grant information**

318 HMS is supported by the Wellcome Trust Institutional Strategic Support Fund [204809] awarded
319 to St. George's University of London. The DARTS study was supported by a DFID/Wellcome
320 Trust Epidemic Preparedness coronavirus grant [220764]. This work was also supported by the
321 St George's Hospital Charity.

322

323 References

- 324 1. WHO. 2021. Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/>. Accessed
325 24th June 2021.
- 326 2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S,
327 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
328 Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken
329 C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV)
330 by real-time RT-PCR. *Euro Surveill* 25:2000045.
- 331 3. DHSC. 2020. QuantuMDx RT-PCR: SARS-CoV-2 Nucleic Acid Detection.
332 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/944909/QuantumDX_TVQ_Report-V0.1-201208.pdf)
333 [_data/file/944909/QuantumDX_TVQ_Report-V0.1-201208.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/944909/QuantumDX_TVQ_Report-V0.1-201208.pdf). Accessed 7th July 2021.
- 334 4. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. 2021. SARS-CoV-2, SARS-
335 CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness:
336 a systematic review and meta-analysis. *Lancet Microbe* 2:e13-e22.
- 337 5. WHO. 2020. COVID 19 Public Health Emergency of International Concern (PHEIC) -
338 Global research and innovation forum: towards a research roadmap.
339 [https://www.who.int/blueprint/priority-diseases/key-](https://www.who.int/blueprint/priority-diseases/key-action/Global_Research_Forum_FINAL_VERSION_for_web_14_feb_2020.pdf)
340 [action/Global_Research_Forum_FINAL_VERSION_for_web_14_feb_2020.pdf](https://www.who.int/blueprint/priority-diseases/key-action/Global_Research_Forum_FINAL_VERSION_for_web_14_feb_2020.pdf).
341 Accessed 7th July 2021.
- 342 6. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, Emperador D,
343 Takwoingi Y, Cunningham J, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price
344 MJ, Taylor-Phillips S, Hooft L, Leeflang MM, Spijker R, Van den Bruel A, Cochrane C-
345 DTAG. 2020. Rapid, point-of-care antigen and molecular-based tests for diagnosis of
346 SARS-CoV-2 infection. *Cochrane Database Syst Rev* 8:CD013705.
- 347 7. Assennato SM, Ritchie AV, Nadala C, Goel N, Tie C, Nadala LM, Zhang H, Datir R,
348 Gupta RK, Curran MD, Lee HH. 2020. Performance Evaluation of the SAMBA II SARS-
349 CoV-2 Test for Point-of-Care Detection of SARS-CoV-2. *J Clin Microbiol* 59:e01262-20.
- 350 8. Gibani MM, Toumazou C, Sohbaty M, Sahoo R, Karvela M, Hon TK, De Mateo S, Burdett
351 A, Leung KYF, Barnett J, Orbeladze A, Luan S, Pournias S, Sun J, Flower B, Bedzo-
352 Nutakor J, Amran M, Quinlan R, Skolimowska K, Herrera C, Rowan A, Badhan A, Klaber
353 R, Davies G, Muir D, Randell P, Crook D, Taylor GP, Barclay W, Mughal N, Moore LSP,
354 Jeffery K, Cooke GS. 2020. Assessing a novel, lab-free, point-of-care test for SARS-
355 CoV-2 (CovidNudge): a diagnostic accuracy study. *Lancet Microbe* 1:e300-e307.
- 356 9. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF, Jin R,
357 Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. 2021. Clinical Performance of the
358 Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter
359 Study. *J Clin Microbiol* 59:e02811-20.
- 360 10. Zhen W, Smith E, Manji R, Schron D, Berry GJ. 2020. Clinical Evaluation of Three
361 Sample-to-Answer Platforms for Detection of SARS-CoV-2. *J Clin Microbiol* 58:e00783-
362 20.
- 363 11. Rabaan AA, Tirupathi R, Sule AA, Aldali J, Mutair AA, Alhumaid S, Muzahed, Gupta N,
364 Koritala T, Adhikari R, Bilal M, Dhawan M, Tiwari R, Mitra S, Emran TB, Dhama K. 2021.
365 Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in
366 COVID-19. *Diagnostics (Basel)* 11:1091.
- 367 12. Chang MC, Hur J, Park D. 2020. Interpreting the COVID-19 Test Results: A Guide for
368 Psychiatrists. *Am J Phys Med Rehabil* 99:583-585.
- 369 13. Chen CJ, Hsieh LL, Lin SK, Wang CF, Huang YH, Lin SY, Lu PL. 2020. Optimization of
370 the CDC Protocol of Molecular Diagnosis of COVID-19 for Timely Diagnosis. *Diagnostics*
371 (Basel) 10:333.

- 372 14. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P,
373 Raoult D. 2020. Viral RNA load as determined by cell culture as a management tool for
374 discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol*
375 *Infect Dis* 39:1059-1061.
- 376 15. Jaafar R, Aherfi S, Wurtz N, Grimaldier C, Van Hoang T, Colson P, Raoult D, La Scola
377 B. 2021. Correlation Between 3790 Quantitative Polymerase Chain Reaction-Positives
378 Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome
379 Coronavirus 2 Isolates. *Clin Infect Dis* 72:e921.
- 380 16. Yang Q, Saldi TK, Gonzales PK, Lasda E, Decker CJ, Tat KL, Fink MR, Hager CR,
381 Davis JC, Ozeroff CD, Muhlrud D, Clark SK, Fattor WT, Meyerson NR, Paige CL,
382 Gilchrist AR, Barbachano-Guerrero A, Worden-Sapper ER, Wu SS, Brisson GR,
383 McQueen MB, Dowell RD, Leinwand L, Parker R, Sawyer SL. 2021. Just 2% of SARS-
384 CoV-2-positive individuals carry 90% of the virus circulating in communities. *Proc Natl*
385 *Acad Sci USA* 118:e2104547118.
- 386 17. Vlek ALM, Wesselius TS, Achterberg R, Thijsen SFT. 2021. Combined throat/nasal
387 swab sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling. *Eur J Clin*
388 *Microbiol Infect Dis* 40:193-195.
- 389
- 390

391 **Tables**

392

393 **Table 1. Patient demographics**

394

Demographic	N (%)
Total number of patients included in study	28
Male Sex	19 (68%)
Median Age (Years)	68
Symptomatic at time of study enrolment	15 (54%)
WHO Ordinal Symptom Severity Scale (OSSS) Baseline Enrolment*	WHO OSSS 4 = 23 (82%) WHO OSSS 5 = 4 (14%) WHO OSSS 6 = 1 (4%)

395

396

397

398

399

* WHO OSSS 4 = Hospitalised, mild disease, no oxygen therapy; WHO OSSS 5 = Hospitalised, oxygen mask or nasal prongs; WHO OSSS 6 = Hospitalised, non-invasive ventilation/high flow oxygen

Table 2. Q-POC™ test performance

Cut-off (Ct)	Total	TP	TN	FP	FN	Sensitivity (95% CI)	Specificity (95% CI)	NPV (95% CI)	PPV (95% CI)
< 40	147	32	106	1	8	80.0% (64.4-91.0)	99.1% (94.9-100)	93.0% (87.7-96.1)	97.0% (81.9-99.6)
< 35	147	31	113	2	1	96.9% (83.8-99.9)	98.3% (93.9-99.8)	99.1% (94.3-99.9)	93.9% (79.7-98.4)

400

401

Abbreviations: TP, true positives; TN, true negatives; FP, false positives; FN, false negatives; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval

Figures




Figure 1. QuantuMDx Q-POC™ and Q-CAS, point-of-care diagnostic for detection of SARS-CoV-2 from nasal swab samples. A. Graphic showing the Q-POC™/Q-CAS workflow. A mid-nasal swab is collected and resuspended in Copan MSwab (3 ml). The tube is inverted 5 times before 400 µl is dispensed into the inlet of the cassette using a pipette. The barcode is scanned, Q-POC™ identifies the cassette, the cassette is inserted and Q-POC™ begins the SARS-CoV-2 assay. A result is displayed on screen in ~30 minutes. B. Key areas of the Q-CAS cassette. Q-POC™ interacts with the self-contained cassette to move the sample from the inlet through the lyophilised reagents and into the shuttle flow PCR region. RT-PCR amplification is detected during shuttling through the detection region. C. Results graph for a positive SARS-CoV-2 sample. The assay results in semi-quantitative PCR curves for SARS-CoV-2 (in red) and sample control, RNaseP (in yellow). This screen is optionally displayed after the main results screen whereby a definitive result is displayed (Positive/Negative/Invalid). Results can be reviewed, printed and uploaded.




Figure 2. Study design.




Figure 3. Longitudinal SARS-CoV-2 Ct values for COVID-19 patient samples. The hospital Ct results that were available are presented as the E gene Ct values for either the Roche (red symbols) or Altona (green symbols) assays and used as day 0. Other data points are Ct values from the laboratory-based SARS-CoV-2 RT-PCR reference assay (black symbols). Any data points above the dashed line are negative and have nominally been given a Ct value of 41 to allow presentation. A Ct cut-off of 35 is represented by the dotted line. Note that both of the RT-PCR assays used by St George's Hospital here have two independently measured targets, one of which is the E gene. The Ct values for the E gene target only were chosen to be presented since the average difference in Ct values between the E gene and the other target within each assay used were -0.18 ± 0.27 (mean \pm SEM; $n = 11$; Range -2.2 to 0.45) and 0.47 ± 0.10 (mean \pm SEM; $n = 12$; Range 0 to 1) for the Roche and Altona assays, respectively.




Figure 4. Comparison between Ct values generated by the laboratory-based SAR-CoV-2 RT-PCR reference assay and the Q-POC™ assay. A. Ct values for SARS-CoV-2 positive samples called by both the reference and Q-POC™ tests ($n = 32$) with Ct values below the 40 and 45 assay cut-off values, respectively. B. Linear regression plot to show the correlation between the reference and Q-POC™ assay Ct values. The line of best fit equation is $y = 0.78x + 12.30$ ($r^2 = 0.76$). C. Bland-Altman plot to evaluate the agreement between the reference and Q-POC™ assay Ct values. The bias between the reference and the Q-POC™ test is -6.7 Ct units (solid line) and the 95% limits of agreement are denoted by the dotted lines.